View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Spondyloarthropathies News

SPONSORED CONTENT
Save
SPONSORED CONTENT
December 13, 2023
2 min read
Save

Work disability due to inflammatory arthritis greater among lower-paid, manual jobs

Work disability due to inflammatory arthritis greater among lower-paid, manual jobs

People who work lower-paid, manual-labor jobs are more likely to discontinue employment in the first 5 years after an early inflammatory arthritis diagnosis, vs. those who work in managerial or professional capacities, according to data.

SPONSORED CONTENT
December 11, 2023
2 min read
Save

Rheumatologists influential in smoking cessation for patients with ankylosing spondylitis

Rheumatologists influential in smoking cessation for patients with ankylosing spondylitis

A rheumatologist’s decision to ask about tobacco use may potentially be the leading factor in whether a patient with ankylosing spondylitis quits smoking, according to data published in Cureus.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
December 07, 2023
2 min read
Save

Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks

Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks

Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.

SPONSORED CONTENT
December 05, 2023
2 min read
Save

Odds of opioid use in autoimmune rheumatic disease decreased 15% annually after 2014

Odds of opioid use in autoimmune rheumatic disease decreased 15% annually after 2014

SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.

SPONSORED CONTENT
November 20, 2023
3 min read
Save

‘This gives us more leeway’: Intravenous secukinumab effective in axial spondyloarthritis

‘This gives us more leeway’: Intravenous secukinumab effective in axial spondyloarthritis

SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to data presented at ACR Convergence 2023.

SPONSORED CONTENT
November 15, 2023
2 min read
Save

Ixekizumab reduces erosion, increases backfill scores in radiographic axial SpA

Ixekizumab reduces erosion, increases backfill scores in radiographic axial SpA

SAN DIEGO — Biologic-naïve patients with radiographic axial spondylarthritis who receive ixekizumab for 16 weeks demonstrate reduced erosion scores and increased backfill scores, according to data presented at ACR Convergence 2023.

SPONSORED CONTENT
November 14, 2023
2 min read
Save

Medicare fails to ‘keep up with’ Medicaid, private market on infliximab biosimilar uptake

Medicare fails to ‘keep up with’ Medicaid, private market on infliximab biosimilar uptake

SAN DIEGO — Compared with Medicaid and private insurance, Medicare has lagged significantly in adopting infliximab biosimilars despite the multiple options now available, according to data presented at ACR Convergence 2023.

SPONSORED CONTENT
November 07, 2023
2 min read
Save

Rheumatology referrals often lack key details of patients’ inflammatory arthritis

Rheumatology referrals often lack key details of patients’ inflammatory arthritis

Key details expressing arthralgia duration, morning stiffness or joint examination findings are often missing from rheumatology referral letters for inflammatory arthritis, according to data published in Rheumatology Advances in Practice.

SPONSORED CONTENT
October 30, 2023
3 min read
Save

Bimekizumab sustains axial spondyloarthritis improvements at 52 weeks

Bimekizumab sustains axial spondyloarthritis improvements at 52 weeks

Patients with axial spondyloarthritis who receive bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, according to data published in the Annals of the Rheumatic Diseases.

SPONSORED CONTENT
October 27, 2023
2 min read
Save

Newly diagnosed psoriatic disease associated with autoimmune disease risk

Newly diagnosed psoriatic disease associated with autoimmune disease risk

Newly diagnosed psoriatic disease may bring with it a significantly increased risk for autoimmune disease incidences, according to a study.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails